Serum Institute wants to advance needle-free injection tech so picked 20% in IntegriMedical
Serum Institute of India (SII) has picked a 20% stake in IntegriMedical as the company envisions a needle-free solution to deliver vaccines. Financial details were not disclosed.
SII CEO Adar Poonawalla said, "At SII, we are
constantly seeking opportunities to invest in technologies that align with our
mission to make healthcare accessible and affordable for people
worldwide."
Speaking about IntegriMedical's US-patented Needle-Free Injection System (N-FIS),
Poonawalla said it represents a significant advancement in drug delivery and
could revolutionise the way vaccines are administered, making the process more
comfortable for patients and healthcare professionals.
Comments
Post a Comment